Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, FluoGuide completed a 15 MSEK directed share issue, Zealand Pharma announced positive phase 1 results while Initiator Pharma finalized its buyback programme. Notably, Scandion Oncology rose nearly 50% without announcing any news.
Only 4 of the 20 listed, Danish biotech companies published news the past week. 7 of the 20 companies had a positive development in their share price for the week and 6 companies have had a positive share price performance year to date. Saniona continues to be the best performing stock this year with a price increase of more than 150%.
Company news the past week
Ascendis Pharma
No news the past week
No news the past week
Cessatech
No news the past week
No news the past week
No news the past week
Evaxion Biotech
No news the past week
Expres2ion
No news the past week
Fluoguide
FluoGuide completes a directed share issue raising SEK 15 million (Link)
Genmab
No news the past week
Gubra
No news the past week
Initiator Pharma
Finalization of share buyback program in Initiator Pharma (Link)
IO Biotech
No news the past week
Pila Pharma
No news the past week
Saniona
No news the past week
Scandion Oncology
No news the past week
SynAct Pharma
No news the past week
ViroGates
No news the past week
Zealand Pharma
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 (Link)
Y-mAbs Therapeutics
No news the past week
2cureX
Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET) (Link)
SELECTED CASES
SHARE PRICE DEVELOPMENTS
On average, the Danish biotech stocks delivered a positive share price performance last week of 1.9%. The overall positive return was largely driven by Scandion Oncology that became the best performing stock with an 49% increase without announcing any company specific news. FluoGuide completed a directed share issue of 15 MSEK while Zealand Pharma announced positive phase 1 results for ZP8936 with potential against obesity and diabetes. Neither news had any significant effect on the share prices of the two companies. Curasight became the worst performing Danish biotech stock with a 9% decrease after a strong share price performance. The best stocks year-to-date include Curasight A/S, Fluoguide A/S, and Saniona AB after soaring 112-152%. Overall the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 4.5%.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
Overview of share price developments the past week, year-to-date and last twelve months
